Join us at the World Orphan Drug Congress Europe in Amsterdam, where our experts will share forward-looking insights into how rare therapies can move from development to market more effectively in Europe. Through discussions on early/expanded access, regulatory alignment, innovative pricing models and patient engagement, this pivotal event brings together global leaders to advance innovation, collaboration and patient-centric pathways in rare disease.
Meet the Sciensus team at the WODC EU 2025
Our speaking sessions
Accelerating a patient-powered pathway from development to market in Europe with rare therapies
Explore ways to better execute EAPs in Europe that ensure an optimised experience, from patient discovery to engagement.
Date: 27 October Time: 14:00-15:00
Speakers:
- Andrew Cummins, VP Business Development at Sciensus;
- Jim McGrath, Director of Commercial Policy at the Irish Pharmaceutical Healthcare Association
Explore how…
- Early/Expanded Access Programmes (EAPs) in Europe are shifting from a stopgap measure to a strategic launch lever
- Insights from EAPs can directly inform broader regulatory, pricing and market access strategies
- Real-world evidence and early engagement can shape both access and reimbursement outcomes
Early/Expanded Access Programs
Explore ways to better execute EAPs in Europe that ensure an optimised experience, from patient discovery to engagement.
Date: 27 October Time: 14:00-15:00
Speakers:
- Andrew Cummins, VP Business Development at Sciensus;
- Jim McGrath, Director of Commercial Policy at the Irish Pharmaceutical Healthcare Association
Explore how…
- Early/Expanded Access Programmes (EAPs) in Europe are shifting from a stopgap measure to a strategic launch lever
- Insights from EAPs can directly inform broader regulatory, pricing and market access strategies
- Real-world evidence and early engagement can shape both access and reimbursement outcomes
Regulatory, Pricing, and Market Authorisation
How best to navigate the complex European environment to ensure the best approach and successful execution of these critical components of the development journey.
Date: 27 October Time: 15:00-16:00
Speakers:
- Doug Niven, European Strategic Consultant;
- Ralph Hughes, Chief Business Officer at Faron Pharmaceuticals;
- Andrew Cummins, VP Business Development at Sciensus
Explore how…
- Regulatory and HTA requirements in Europe create unique challenges for launch planning and evidence generation
- Innovative pricing and reimbursement models are evolving for rare and specialty therapies
- Market prioritisation in Europe requires balancing patient need with commercial viability
Patient Engagement and In-Market Support
What are best practices for patient-focused support programs, distribution, and digital solutions post-approval and in-market.
Date: 27 October Time: 16:00-17:00
Speakers:
- Ray Huml, Vice President Rare Disease Strategy;
- Mathieu Loiseau, Director of Rare Clinical Services;
- Sophie Muir, CEO of the Timothy Syndrome Foundation;
- Pat Furlong, President and founder of Parent Project Muscular Dystrophy;
- Lara Bloom; CEO of Ehlers-Danlos Society
Explore how
- Best practices in patient-focused support programs can strengthen trust, adherence, and quality of life
- Digital solutions and platforms are reshaping post-approval engagement, data collection, and community support
- Patient advocacy organisations are addressing real-world challenges, from awareness to equity of access
Keynote panel
Looking ahead, what does the future for Europe’s Life Science Strategy and what does it mean for rare diseases?
Date: Tuesday 28th October
Time: 9:10am – 10:00am
Speakers:
- Raymond Huml, Vice President, Rare Disease Strategy, Sciensus
- Fabienne Bartoli, Inspector General, French National Authority for Health
- Christina Kyriakopoulou, Policy Officer, Health Research Programmes, European Commission
- Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
- Sophie Schmitz, Managing Partner, Partners4Access
- Rosa Castro, Public Affairs Director, EURORDIS
We bring breakthroughs closer to rare-disease patients
Let’s connect at WODC EU 2025. As a leading European life sciences organisation with over 30 years of experience specialising in rare disease drugs, we provide end-to-end rare disease commercialisation and consulting services to make sure your treatment reaches the patients who need it most.
Expertise that makes the difference
Leveraging over 30 years of clinical experience, deep therapeutic expertise and personalised digital innovation, we help biopharma, CROs and CCOs bring treatments to patients across Europe faster.
$ 380,000,000 +
orphan drugs bought and sold per year
0
relationships with healthcare providers
0 +
units of orphan medicine supplied
Book a meeting
Interested in meeting with our team at the event? Fill out the form below to book a time. We’ll reach out shortly to coordinate a meeting that fits your schedule. We look forward to connecting!